Testicular Neoplasms

Webpage with basic information on the cohort study and link to the electronic case report form (eCRF) portal

Kantonsspital St.Gallen; Onkologie/Haematologie

Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS

Diagnostic performance and the clinical impact of a variety of tests, including conventional radiographs, computed tomographies (CT), abdominal ultrasound, serum tumour markers (AFP, beta-HCG and LDH) and clinical signs and symptoms aimed at early detection of relapse after curative therapy with documented complete remission.

Dr. med. Christian Rothermundt

Dr. med.

German Testicular Cancer Study Group

Seminoma

Stage IIA: 1 infusion Carboplatin AUC7 followed by 15 x 2 Gy involved node radiotherapy Stage IIB: 1 infusion Carboplatin AUC7 followed by 18 x 2 Gy involved node radiotherapy

Carboplatin

Involved node RT

Aachen Universitätsklinik

Berlin Universitätsklinik Charité

Berlin Vivantes - Urban

Berlin Vivantes - Neukölln

Universitaetsklinikum Düsseldorf

Klinik Essen-Mitte

Hamburg Universitätsklinikum - Eppendorf

Krefeld Maria-Hilf Krankenhaus

Universitätsklinikum Köln

Klinikum Harlaching

Universitätsklinikum Tübingen

Universitätsklinikum Ulm

Kantonspital Aarau

Kantonsspital Baden

Universitaetsspital-Basel

Istituto Oncologico della Svizzera Italiana (IOSI)

Inselspital Bern

Spitalzentrum Biel

Kantonsspital Graubuenden

Centre Hospitalier Universitaire Vaudois CHUV

Kantonsspital Olten

Hopital de Sion

Kantonsspital - St. Gallen

Regionalspital Thun

Kantonsspital Winterthur

Therapy De-escalation in Seminoma Stage IIA/B

Carboplatin Chemotherapy and Involved Node Radiotherapy in Stage IIA/B Seminoma

PFS is defined as the time from registration until one of the following events occurs:
PD or relapse, defined as progression according to the modified trial-specific version of RECIST 1.1 or a rising level of the tumor marker beta-hCG over the ULN (value must be confirmed by a second measurement). Presence of non-seminoma germ cell tumor has to be excluded in the latter case.
Death from any cause.

AEs are collected from inclusion until 30 days after the end of treatment

AEs will be collected from 30 days after the end of treatment until the end of the follow-up phase

from registration until documented progressive disease, relapse or death due to tumor.

from registration to the date of death from any cause

from registration to the date of death due to seminoma

from registration to the date of failure of PFS

from first localization where recurrent tumor disease is detected

seminoma/إعياء

Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS

Therapy De-escalation in Seminoma Stage IIA/B

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم